Listed pharmas’ stock prices dropped by 17% after Hanmi incident

Published: 2016-10-11 14:52:01

Updated: 2016-10-11 14:52:01

Stock prices of listed pharmaceutical companies collapsed by 17% after the Hanmi Pharm crisis.

Moreover, approximately KRW 9 trillion was studied to evaporate from these listed pharmas’ market capitalization by the impact.

Since Hanmi Pharm signed an antibody technology license agreement of KRW 1 trillion with a Roche’s affiliate Genentech on the 29^th of September and made a late notificati...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.